what are the risks of taking glp 1 Long-Term Effects GLP-1 Medications: You Should Know GLP-1 Drugs and Eating Disorders:

Most patients were Caucasian (78.7% and 78.4% in each cohort, respectively), as recorded in the electronic health record

Though the structure was not publicly disclosed, AZD2820 was reported to be a partial hMC4R agonist (EC 50 = 1 nM, E max = 38%) and had no detectable agonist activity on hMC3R as shown in Table 1 ( ad libitum or were calorically restricted to induce 20% body weight loss prior to 12-week treatment with either 2.64, 10.8, or 53.4 nmol of AZD2820 per day via SC minipump infusion

doi: 10.1097/CCE.0000000000000543

It goes undertreated not because it is complex, but because it goes untested

Diarrhea May occur especially during dose adjustments

J Vet Med Sci 68:213217 Stach K, Stach W, Augoff K (2021) Vitamin B6 in health and disease